Short answer
LivaNova PLC (LIVN) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). LivaNova reported financial results for the quarter ended September 30, 2026.
LivaNova PLC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- LivaNova reported financial results for the quarter ended September 30, 2026
- Management conference call scheduled November 4, 2026 at 1 p.m. London time
- Detailed financial figures and outlook available in Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $393.1M, up 9.9% reported and 10.0% constant currency, with Cardiopulmonary and Neuromodulation each growing over 10%
- Adjusted EPS $1.23 versus $1.11, while GAAP diluted EPS fell to $0.11 from $0.49 due to higher exceptional operating costs
- Full-year constant-currency revenue growth raised to 9%-10% from 8%-9%, with adjusted EPS guidance increased to $4.40-$4.50
- Oxygenator production line operational, expanding capacity to address strong customer demand and potentially reduce supply constraints
- New Category I CPT codes for hypoglossal nerve stimulation expected January 1, 2028, supporting longer-term reimbursement and market-access potential
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other LivaNova PLC 8-K filings
Get the next LIVN 8-K as it lands
Follow LIVN for push alerts, or ask the research agent what this filing means.